Company: GANX
Filing Date: 2025-12-03
Form Type: S-8
Source: 0001104659-25-118118
Chunk: 1

Company: Gain Therapeutics, Inc.
Filing Date: 2025-12-03
Form: S-8
Chunk 1
---

<div align='center'>EXPLANATORY NOTE</div>

Pursuant to General
Instruction E to Form S-8, Gain Therapeutics, Inc. (the “Registrant”) is filing this Registration
Statement on Form S-8 (the “S-8 Registration Statement”) with the Securities and Exchange Commission (the
“Commission”) to register 1,627,955 additional shares (“Evergreen Shares”) of the
Registrant’s common stock, par value $0.0001 per share (“Common Stock”), reserved for issuance under
the Gain Therapeutics, Inc. 2022 Equity Incentive Plan (the “2022 Plan”), pursuant to the provisions of
the 2022 Plan providing for an automatic annual increase by an amount equal to 6% of the total number of Common Stock shares outstanding
on December 31 of the preceding calendar year. In accordance with the instructional note to Part I of Form S-8 as promulgated
by the Commission, the information specified by Part I of the Form S-8 has been omitted from this S-8 Registration Statement.

This S-8 Registration
Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which Registration
Statements of the Registrant on Form S-8 relating to the same benefit plan is effective. The Registrant previously registered Common
Stock for issuance under the 2022 Plan under Registration Statements on Form S-8, filed with the Commission on July 15, 2022 (File No. 333-266142), May 30, 2023 (File No. 333-272255) and September 19, 2024 (File No. 333-282205).
Pursuant to General Instruction E to Form S-8, this S-8 Registration Statement hereby incorporates by reference the contents of
the Registration Statements referenced above.

<div align='center'>Part II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</div>

Item 3. Incorporation of Documents by Reference.

The following documents, which have been filed
by the Registrant with the Commission pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated herein by reference:

| · 
 · | The Registrant’s                                                                                                                                                                                                                         
 latest annual report on Form 10-K for the fiscal year ended December 31, 2024, as filed with the Commission on March 27,